Differences in oxylipin profile in psoriasis versus psoriatic arthritis

Oxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory...

Descripción completa

Detalles Bibliográficos
Autores: Coras, Roxana|||0000-0001-9547-218X, Kavanaugh, Arthur, Kluzniak, Angela, Holt, Dustina, Weilgosz, Amy, Aaron, Armando, Quehenberger, Oswald, Ritchlin, Christopher, Guma, Monica|||0000-0003-1951-9411
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:248848
Acceso en línea:https://ddd.uab.cat/record/248848
https://dx.doi.org/urn:doi:10.1186/s13075-021-02575-y
Access Level:acceso abierto
Palabra clave:Psoriatic arthritis
Psoriasis
Enthesitis
Oxylipins
Skin disease
id ES_285dbd771122d0bfcfb442d2cd7cff06
oai_identifier_str oai:ddd.uab.cat:248848
network_acronym_str ES
network_name_str España
repository_id_str
spelling Differences in oxylipin profile in psoriasis versus psoriatic arthritisCoras, Roxana|||0000-0001-9547-218XKavanaugh, ArthurKluzniak, AngelaHolt, DustinaWeilgosz, AmyAaron, ArmandoQuehenberger, OswaldRitchlin, ChristopherGuma, Monica|||0000-0003-1951-9411Psoriatic arthritisPsoriasisEnthesitisOxylipinsSkin diseaseOxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers. Consecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC/TJC 66/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1. Twenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (> 2.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without. The AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/248848https://dx.doi.org/urn:doi:10.1186/s13075-021-02575-yreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2488482026-06-06T12:50:31Z
dc.title.none.fl_str_mv Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title Differences in oxylipin profile in psoriasis versus psoriatic arthritis
spellingShingle Differences in oxylipin profile in psoriasis versus psoriatic arthritis
Coras, Roxana|||0000-0001-9547-218X
Psoriatic arthritis
Psoriasis
Enthesitis
Oxylipins
Skin disease
title_short Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_full Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_fullStr Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_full_unstemmed Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_sort Differences in oxylipin profile in psoriasis versus psoriatic arthritis
dc.creator.none.fl_str_mv Coras, Roxana|||0000-0001-9547-218X
Kavanaugh, Arthur
Kluzniak, Angela
Holt, Dustina
Weilgosz, Amy
Aaron, Armando
Quehenberger, Oswald
Ritchlin, Christopher
Guma, Monica|||0000-0003-1951-9411
author Coras, Roxana|||0000-0001-9547-218X
author_facet Coras, Roxana|||0000-0001-9547-218X
Kavanaugh, Arthur
Kluzniak, Angela
Holt, Dustina
Weilgosz, Amy
Aaron, Armando
Quehenberger, Oswald
Ritchlin, Christopher
Guma, Monica|||0000-0003-1951-9411
author_role author
author2 Kavanaugh, Arthur
Kluzniak, Angela
Holt, Dustina
Weilgosz, Amy
Aaron, Armando
Quehenberger, Oswald
Ritchlin, Christopher
Guma, Monica|||0000-0003-1951-9411
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Psoriatic arthritis
Psoriasis
Enthesitis
Oxylipins
Skin disease
topic Psoriatic arthritis
Psoriasis
Enthesitis
Oxylipins
Skin disease
description Oxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers. Consecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC/TJC 66/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1. Twenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (> 2.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without. The AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/248848
https://dx.doi.org/urn:doi:10.1186/s13075-021-02575-y
url https://ddd.uab.cat/record/248848
https://dx.doi.org/urn:doi:10.1186/s13075-021-02575-y
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404941733330944
score 15,300719

Similares en LA Referencia